Published on 30/11/2025

Identity Testing: Sequencing, Proteomics, and Flow Cytometry

Introduction to Identity Testing in Biologics

Identity testing is a fundamental aspect of the validation process for biologics and advanced therapy medicinal products (ATMP). It encompasses various methodologies and technologies including sequencing, proteomics, and flow cytometry. The validation of identity is critical as it assures product integrity, which is paramount in the manufacturing process and necessary for regulatory compliance. This step-by-step guide outlines the key processes involved in identity testing, focusing on important components such as viral clearance validation, spiking studies, closed systems, and single-use systems.

Understanding the Goals and Importance of Viral Clearance Validation

Viral clearance validation is essential to ensure that biologics are free from viral contaminants that could pose serious health risks. This validation demonstrates the efficacy of the manufacturing process in removing or inactivating viruses. Effective viral clearance methods are required by regulatory authorities such as the FDA and the EMA. The validation typically involves various stages, including:

• Assessment of Risk: Identifying potential viral contaminants and assessing their impact on product safety.
• Development of a Viral Clearance Plan: Establishing the strategy and methods for viral clearance, tailored for the specific product being developed.
• Execution of Studies: Conducting studies such as spiking studies to determine the effectiveness of viral clearance steps.
• Data Analysis: Compiling and analyzing data to prepare validation reports and ensure compliance with regulatory expectations.

Incorporating stringent viral clearance measures within the validation plan is necessary to mitigate risks associated with viral contamination. It is vital to validate the systems and processes used, both during early development and commercial manufacturing phases.

The Role of Spiking Studies in Identity Testing

Spiking studies play a pivotal role in viral clearance validation by simulating how the manufacturing process would respond to viral contamination. These studies involve intentionally introducing a known quantity of a virus into the production system and assessing whether subsequent purification steps effectively remove or inactivate the virus. The process generally includes:

• Selection of Suitable Viruses: Choosing surrogate viruses that are representative of potential contaminants can help gauge the effectiveness of viral clearance strategies.
• Preparation of Spiked Samples: Creating samples that reflect the manufacturing process while spiking them with the virus in question.
• Execution of Validation Tests: Performing the established process (e.g., filtration, chromatography) on spiked samples to evaluate viral clearance.
• Evaluation of Results: Comparing the viral load before and after purification steps to ascertain clearance efficacy.

Data from spiking studies helps justify the implementation of processes intended to assure patient safety and regulatory compliance. By demonstrating the effectiveness of viral clearance under worst-case scenarios, these studies provide pivotal data for the licensing of biologics.

Implementing Closed Systems and Single-Use Systems

The integration of closed systems and single-use systems into production workflows is becoming increasingly common in biopharmaceutical manufacturing. These systems offer unique advantages in terms of reducing contamination risks and enhancing operational efficiency. Key considerations for implementing these systems include:

• Design and Configuration: Closed systems are designed to prevent exposure to the environment during manufacturing. Effective design includes appropriate barriers and control systems, ensuring aseptic processing.
• Single-Use Technologies: The adoption of single-use components minimizes the need for cleaning and sterilization, which helps mitigate risks associated with cross-contamination.
• Viral Clearance Impact Assessment: Identifying how closed systems and single-use technologies may affect the existing viral clearance strategies is pivotal in ensuring they are equally effective.
• Regulatory Compliance: Ensure alignment with regulatory guidelines on the validation of these systems, including adherence to standards set forth by PIC/S.

In an environment where product safety is paramount, closed and single-use systems provide practical solutions for maintaining stringent aseptic controls, reducing the risk of viral contaminations effectively.

Aseptic Controls and Their Relevance to Annex 1

The EU’s Annex 1 to the GMP Guidelines provides comprehensive requirements for manufacturing sterile medicinal products. Aseptic controls play a crucial role in complying with these guidelines. The key elements to consider when integrating aseptic controls into identity testing include:

• Facility Design: The design of a manufacturing facility must support aseptic processes. This includes appropriate airflow systems, controlled temperature, and humidity levels.
• Personnel Training: Ensuring that all personnel are trained in aseptic techniques reduces the likelihood of contamination during manufacturing.
• Environmental Monitoring: Continuously monitoring the environment for viable and non-viable particles is critical to prevent contamination.
• Process Validation: Comprehensive validation of aseptic processing is required to demonstrate that the product meets identity and quality requirements, as outlined in Annex 1.

Adhering to aseptic controls according to Annex 1 requirements will support the identification of products and ensure patient safety through effective risk management.

Ensuring Potency Identity CQAs Align with Regulatory Expectations

Critical Quality Attributes (CQAs) concerning potency and identity are essential in demonstrating the safety and efficacy of biologics and ATMPs. When developing a plan for identity testing, it is imperative to include methods for assessing these attributes, which usually encompasses:

• Defining CQAs: Closely monitoring characteristics such as the molecular weight, structure, and biological activity of the product.
• Analytical Method Development: Implementing robust methods, such as mass spectrometry or enzyme-linked immunosorbent assay (ELISA), to accurately characterize identity attributes.
• Integration of Data: Ensuring that data from various analytical methods aligns to provide comprehensive evidence of product identity and its potency.
• Alignment with Regulatory Frameworks: Complying with guidelines set forth in documents such as ICH Q5A(R2), which address virulent agents’ control and the safety of ATMPs.

By aligning potency identity CQAs with regulatory expectations, biopharmaceutical manufacturers can effectively support product registrations and follow-up regulatory reviews.

Chain of Identity Custody and Its Importance in Validation

Maintaining a robust chain of identity custody (COI) ensures that the product’s identity is preserved throughout the manufacturing process. This is a critical factor in identity testing and validation. Best practices for managing COI include:

• Documentation: Implementing rigorous documentation practices ensures traceability throughout the production process, from raw material sourcing to final product release.
• Monitoring Transfers: Closely monitoring all transfers and movements of materials during the manufacturing process minimizes the risk of mix-ups or contamination.
• Auditing Practices: Regular audits should be conducted to verify the integrity of the COI throughout the production process, in compliance with cGMP standards.
• Training and Awareness: Ensuring that all relevant personnel understand the importance of maintaining COI will help mitigate risks related to identity claims.

A robust chain of identity custody is essential for successful identity testing, regulatory compliance, and maintaining market trust in the product.

PPQ and CPV Tailoring for ATMPs

Process Performance Qualification (PPQ) and Continued Process Verification (CPV) are pivotal elements in the validation lifecycle of biologics and ATMPs. Tailoring these approaches for ATMPs is critical, as they often involve complex manufacturing processes. Key steps include:

• Risk Assessment: Conducting thorough risk assessments to identify potential failure modes and their impact on critical quality attributes.
• Defining Acceptance Criteria: Establishing stringent acceptance criteria for the successful validation of manufacturing processes.
• Continual Monitoring: Implementing provisions for continual monitoring of production processes to manage variability and ensure consistent product quality.
• Adjustments Based on Data: Leveraging the data gathered from monitoring systems to make proactive adjustments to the manufacturing process.

By effectively tailoring PPQ and CPV for ATMPs, organizations can assure product quality and meet the expectations outlined by regulatory agencies, supporting the integrity of their biologics throughout their lifecycle.

Conclusion

Identity testing in biologics and ATMPs is paramount for assuring product integrity, patient safety, and regulatory compliance. By implementing thorough viral clearance validation, engaging in spiking studies, utilizing closed and single-use systems, and adhering to aseptic controls per Annex 1, organizations can navigate the complexities of identity testing effectively. Additionally, aligning potency identity CQAs, maintaining a robust chain of identity custody, and tailoring PPQ and CPV for ATMPs reinforces a comprehensive validation framework. By adhering to these practices, pharmaceutical professionals can ensure a safer product that satisfies both regulatory requirements and market expectations.